- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02982902
T Cell Therapy of Opportunistic Cytomegalovirus Infection
Antigen Specific Adoptive T Cell Therapy for Opportunistic Cytomegalovirus Infection Occurring After Stem Cell Transplant
The purpose of this study is to determine if a specific type of cell-based immunotherapy, using T-cells from a donor that are specific against cytomegalovirus (CMV) is feasible to treat infections by CMV.
Adoptive T-cell therapy is an investigational (experimental) therapy that works by using the blood of a donor and selecting the T-cells that can respond against a specific infectious entity. These selected T-cells are then infused to the patient, to try to give the immune system the ability to fight the infection. Adoptive T-cell therapy is experimental because it is not approved by the Food and Drug Administration (FDA).
Study Overview
Status
Intervention / Treatment
Detailed Description
The primary objective of this study is to determine the feasibility of the treatment of opportunistic cytomegalovirus (CMV) infections after hematopoietic stem cell transplant (HSCT) with virus-specific, antigen-selected T-cells, selected using the CliniMACS prodigy system.
Secondary Objective(s)
- To describe the safety profile of the infusion of CMV- specific, antigen selected T-cells.
- To describe the toxicities related to infusion of CMV- specific, antigen selected T-cells.
- To describe the rate of eradication of opportunistic CMV infections after HSCT and and treatment with CMV-specific, antigen-selected T-cells using the CliniMACS Prodigy System.
This feasibility study will include a single treatment cohort.
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Mari H Dallas, MD
- Phone Number: 1-800-641-2422
- Email: CTUReferral@UHhospitals.org
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44106-5065
- Recruiting
- University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
-
Contact:
- Mari H Dallas, MD
- Phone Number: 800-641-2422
- Email: CTUReferral@UHhospitals.org
-
Principal Investigator:
- Mari H Dallas, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must have received allogeneic hematopoietic stem cell transplant and be greater than 30 days post-transplant at the time of registration
Patients must have documented opportunistic CMV infection, or reactivation; the criteria include (both of the following criteria must be met)
- Patients may have asymptomatic viremia (>1000 copies/ml) OR presence of symptoms secondary to CMV infection, AND
Patients must have ONE OF THE NEXT FOUR CRITERIA:
- Absence of an improvement of viral load after ≥ 14 days of antiviral therapy with ganciclovir, valganciclovir or foscarnet (decrease by at least 1 log, i.e. 10-fold) or
- New, persistent and/or worsening CMV-related symptoms, signs and/or markers of end organ compromise while on antiviral therapy with ganciclovir, valganciclovir or foscarnet, or
- Have contraindications or experience adverse effects of antiviral therapy with ganciclovir, valganciclovir or foscarnet.
- Second recurrence of CMV viremia, CMV-related symptoms, signs and/or markers of end organ compromise.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3
- Women of child-bearing potential and men must agree to use adequate contraception (double barrier method of birth control or abstinence) 4 weeks prior to study entry, for the duration of study participation and for 3 months after completing treatment.
- Subjects must have the ability to understand and the willingness to sign a written informed consent document, or assent document.
Exclusion Criteria:
- Pregnant or breastfeeding women are excluded from this study.
- Patients with opportunistic viral infections other than CMV.
- Patients with active, grade 2-4, acute graft vs. host disease (GVHD), chronic GVHD or any condition requiring high doses of glucocorticosteroid (>0.5 mg/kg/day prednisone or its equivalent) as treatment
- Treatment with antithymocyte globulin within 28 days of planned infusion of virus - specific, antigen selected T cells.
- Treatment with virus - specific T cells within 6 weeks (42 days) of planned infusion.
Donor eligibility
- Related donor of T cells must be at least partially HLA compatible, matching with recipient in at least 3/6 HLA loci (HLA-A, HLA-B, and HLA-DRB1 loci will be considered for this).
- Must have evidence of a serologic response (i.e. be seropositive) against CMV.
- Age ≥ 18 years
- Must meet the criteria for donor selection defined in the Standard Operating Procedures of University Hospitals Seidman Cancer Center Stem Cell Transplant Program
- Must be capable of undergoing a single standard 2 blood volume leukapheresis or donation of one unit of whole blood
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CMV specific adoptive t-cells
This study involves a one-time infusion of the experimental CMV specific adoptive t-cells.
After this infusion, patients will be followed for 4 weeks.
|
It is expected that the cell dose will be in the range of 10^3 - 10^5 virus - specific, antigen selected T cells per kg of recipient weight.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events
Time Frame: Up to 100 days after transplant
|
To determine the feasibility of the intervention, the study will record the incidence of adverse events, including graft versus host disease and other complications will be evaluated using binomial distribution theory and their 95% confidence intervals (CIs) will be also estimated using Wilson's method
|
Up to 100 days after transplant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Eradication rate of opportunistic CMV infections
Time Frame: Up to 100 days after transplant
|
The eradication rate will be the disappearance of opportunistic CMV infections with the use of CMV-specific, antigen-selected T cells using the CliniMACS Prodigy System over the total number CMV infections.
|
Up to 100 days after transplant
|
response rate
Time Frame: Up to 100 days after transplant
|
A response rate of 25% is considered unacceptable; and the anticipated response rate is approximately 55% for the study population using the cell therapy.
|
Up to 100 days after transplant
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mari H Dallas, MD, University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CASE1Z16
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cytomegalovirus Infections
-
University of Alabama at BirminghamEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingMaternal Cytomegalovirus Infections | Cytomegalovirus CongenitalUnited States
-
University of Sao Paulo General HospitalCompletedCytomegalovirus DiseaseBrazil
-
Mayo ClinicCompletedCytomegalovirus InfectionUnited States
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus InfectionUnited States, France, Germany, Italy, Japan, United Kingdom
-
Assistance Publique - Hôpitaux de ParisCompletedCongenital Cytomegalovirus InfectionFrance
-
National Institute of Allergy and Infectious Diseases...Terminated
-
Institut PasteurCompletedCongenital Cytomegalovirus InfectionFrance
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus (CMV) InfectionsUnited States, Australia, Canada, Finland, Israel, Russian Federation, Spain
-
Assistance Publique - Hôpitaux de ParisCompletedCongenital Cytomegalovirus InfectionFrance
-
The George Washington University Biostatistics...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedCongenital Cytomegalovirus Infection | Maternal Cytomegalovirus InfectionUnited States
Clinical Trials on CMV specific adoptive t-cells
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...CompletedCytomegalovirus Infection | Adenovirus InfectionUnited States
-
H. Kim LyerlyNational Cancer Institute (NCI); National Institutes of Health (NIH)TerminatedAllogeneic Stem Cell TransplantationUnited States
-
M.D. Anderson Cancer CenterMiltenyi Biotec B.V. & Co. KGCompletedLymphoma | LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingDiffuse Large B-Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Mantle Cell Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Transformed Non-Hodgkin LymphomaUnited States
-
Dana-Farber Cancer InstituteBrigham and Women's HospitalCompletedNasopharyngeal CarcinomaUnited States
-
University of Wisconsin, MadisonUniversity of Wisconsin Carbone Cancer Center (UWCCC)RecruitingCytomegalovirus Infections | Opportunistic Infections | CMV Infection | CMV ViremiaUnited States
-
University of Wisconsin, MadisonTerminatedCytomegalovirus Infections | Solid Organ TransplantUnited States
-
Catherine BollardM.D. Anderson Cancer CenterRecruitingViral InfectionUnited States
-
Memorial Sloan Kettering Cancer CenterCompleted
-
Prof. Tobias FeuchtingerEuropean Commission; Simbec-Orion Group Ltd, Merthyr Tydfil, UK; Miltenyi Biotec... and other collaboratorsRecruitingCMV Infection | EBV Infection | Stem Cell Transplant Complications | AdV InfectionBelgium, Spain, France, Germany, Italy, Netherlands